Bio-Rad Laboratories said this week that Ted Love has been appointed to its board of directors, bringing the company back into compliance with New York Stock Exchange listing requirements.
Love will be on the board's audit committee. The NYSE requires a listed company to have three independent directors on its audit committee.
Love is the executive vice president of R&D at Onyx Pharmaceuticals. Prior to that, he was president, CEO, and a board member of Nuvelo. He will stand for election along with Bio-Rad's other board members at the company's annual meeting on April 27.